Retatrutide: Research Overview, Mechanism of Action & Lab Supply Standards
A summary of published research on Retatrutide — a triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, currently one of the most actively studied compounds in metabolic research.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly and Company. It is a triple agonist designed to simultaneously activate three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple receptor engagement distinguishes it from dual agonists like tirzepatide (GLP-1/GIP) and single agonists like semaglutide (GLP-1 only).
Retatrutide remains an investigational compound and has not received regulatory approval from Health Canada, the FDA, or any other regulatory authority as of this writing. All material is supplied strictly for laboratory and research use only. Researchers should note that due to its investigational status, Retatrutide is among the most actively studied compounds in current metabolic and endocrinological research.
Proposed Mechanisms of Action
GLP-1 Receptor Agonism
GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central satiety signaling. This is the same pathway targeted by semaglutide and the foundational mechanism of the GLP-1 drug class.
GIP Receptor Agonism
GIP receptor co-activation enhances insulin secretion in a glucose-dependent manner and has been proposed to improve the tolerability profile of GLP-1 receptor agonism by modulating gastrointestinal side effect pathways. GIP receptor activity also influences adipose tissue metabolism and bone density endpoints in preclinical models.
Glucagon Receptor Agonism
The glucagon receptor component is what distinguishes Retatrutide from tirzepatide. Glucagon receptor activation increases energy expenditure through thermogenic mechanisms — particularly hepatic fat oxidation and brown adipose tissue activation. In rodent models, this third receptor component drives additive metabolic effects beyond those achievable with dual agonism alone.
Hepatic Fat Reduction
The combination of all three receptor pathways produces pronounced effects on hepatic lipid metabolism in preclinical models. Liver fat reduction has been documented as a notable endpoint in both rodent studies and early Phase 2 clinical data, making Retatrutide a compound of significant interest for metabolic liver disease research.
Selected Published Research
Coskun T, et al. — Cell Metabolism, 2022
Preclinical and early Phase 1 data on Retatrutide's activity at GLP-1, GIP, and glucagon receptors. Documents dose-dependent metabolic effects in rodent models and initial human pharmacokinetic data.
Jastreboff AM, et al. — New England Journal of Medicine, 2023
Phase 2 randomized controlled trial reporting body weight reduction endpoints across dose groups over 48 weeks. One of the most cited studies on Retatrutide's metabolic effects in human subjects.
Day JW, et al. — Nature Chemical Biology, 2009
Foundational dual receptor agonism paper establishing the research rationale for combining GLP-1 and glucagon receptor activity — the mechanistic basis that Retatrutide extends to triple agonism.
Pocai A, et al. — Diabetes, 2009
Rodent study examining glucagon receptor activation's role in thermogenesis and energy expenditure — the third receptor component targeted by Retatrutide and the basis for its proposed metabolic advantage over dual agonists.
Purity Standards for Research Use
HPLC Purity
As a larger peptide with multiple functional domains, Retatrutide purity verification by HPLC is critical. Research-grade material should meet ≥99%+ HPLC purity. Any related impurities or truncated sequence fragments must be accounted for in the COA.
Mass Spectrometry
MS identity confirmation is particularly important for Retatrutide given the number of structurally similar GLP-1 agonist peptides in the research supply market. Confirmed molecular weight and fragmentation pattern verification distinguish authentic Retatrutide from semaglutide, liraglutide, or tirzepatide analogues.
Lyophilization & Storage
Retatrutide should be stored lyophilized at -20°C. The peptide is sensitive to repeated freeze-thaw cycles and oxidative degradation.
Certificate of Analysis
Given Retatrutide's investigational status and the high research interest in this compound, batch-specific COA documentation with HPLC chromatogram and MS data is essential. Researchers should retain COA records as part of lab documentation protocols.
Sourcing Retatrutide in Canada
ACCUTIDE Research Supply provides Retatrutide tested to ≥99%+ HPLC purity with batch-specific COA and MS identity confirmation. All material ships Canada-wide, lyophilized, for laboratory research use only.
Retatrutide — Canadian Research Supply
≥99%+ HPLC · COA every batch · Ships Canada-wide · RUO
Often Researched With
Compounds frequently co-investigated alongside Retatrutide in preclinical research literature.
Research Use Only Disclaimer: All information is provided for scientific research and educational purposes only. Retatrutide is an investigational compound and has not received regulatory approval from Health Canada or any other regulatory authority. Material supplied by ACCUTIDE Research Supply is strictly for laboratory research use (RUO) — not for human or animal consumption or therapeutic use.